Atea Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for AVIR, updated each market day.
AVIR AI Sentiment
AI predicts Atea Pharmaceuticals, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Atea Pharmaceuticals, Inc. Common Stock
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Sector
Exchange
Market Cap
$465,284,964
Cap Tier
Employees
55
Headquarters
BOSTON, MA
Listed Since
Oct. 30, 2020
Website
AVIR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AVIR Volatility
Atea Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
